Compare Swedish Orphan Biovitrum AB with Similar Stocks
Dashboard
1
Healthy long term growth as Net Sales has grown by an annual rate of 12.34%
2
With a growth in Net Profit of 183.93%, the company declared Very Positive results in Jun 25
3
With ROE of 11.90%, it has a attractive valuation with a 2.75 Price to Book Value
4
Company is among the highest 1% of companies rated by MarketsMojo across all 4,000 stocks
5
Consistent Returns over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
SEK 117,589 Million (Large Cap)
23.00
NA
0.00%
0.34
19.23%
3.27
Revenue and Profits:
Net Sales:
6,175 Million
(Quarterly Results - Jun 2025)
Net Profit:
634 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
1699.09%
0%
1699.09%
6 Months
1967.92%
0%
1967.92%
1 Year
2316.36%
0%
2316.36%
2 Years
1542.32%
0%
1542.32%
3 Years
2588.95%
0%
2588.95%
4 Years
3869.91%
0%
3869.91%
5 Years
3153.11%
0%
3153.11%
Swedish Orphan Biovitrum AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
12.34%
EBIT Growth (5y)
8.66%
EBIT to Interest (avg)
6.87
Debt to EBITDA (avg)
1.73
Net Debt to Equity (avg)
0.33
Sales to Capital Employed (avg)
0.45
Tax Ratio
12.54%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
11.02%
ROE (avg)
10.77%
Valuation key factors
Factor
Value
P/E Ratio
23
Industry P/E
Price to Book Value
2.75
EV to EBIT
18.51
EV to EBITDA
11.77
EV to Capital Employed
2.36
EV to Sales
4.42
PEG Ratio
0.23
Dividend Yield
NA
ROCE (Latest)
12.73%
ROE (Latest)
11.90%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Bullish
Bullish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot : Mar 2024
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
6,175.00
5,442.00
13.47%
Operating Profit (PBDIT) excl Other Income
2,152.00
1,555.00
38.39%
Interest
216.00
337.00
-35.91%
Exceptional Items
-237.00
-30.00
-690.00%
Consolidate Net Profit
634.00
224.00
183.04%
Operating Profit Margin (Excl OI)
204.50%
117.60%
8.69%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 13.47% vs 11.70% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 183.04% vs 0.90% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
26,027.00
22,124.00
17.64%
Operating Profit (PBDIT) excl Other Income
9,538.00
7,825.00
21.89%
Interest
1,240.00
1,111.00
11.61%
Exceptional Items
-195.00
-484.00
59.71%
Consolidate Net Profit
3,879.00
2,409.00
61.02%
Operating Profit Margin (Excl OI)
223.40%
210.50%
1.29%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 17.64% vs 17.74% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 61.02% vs -8.68% in Dec 2023
About Swedish Orphan Biovitrum AB 
Swedish Orphan Biovitrum AB
Pharmaceuticals & Biotechnology
Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others. On September 9, 2013, the Company acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen, the biotechnology company based in the United States.
Company Coordinates 
Company Details
Tomtebodavagen 23A , SOLNA None : 112 76
Registrar Details






